SLC38A7 and familial pancreatic carcinoma: In this study, we first examined the combinations of seven distinct types of cytotoxic anticancer drugs with an amino acid transporter LAT1 inhibitor, nanvuranlat (NANV; JPH203 or KYT-0353), on the growth of pancreatic cancer MIA PaCa-2 cells (Fig. 1B).